HomeCompareICVX vs QYLD

ICVX vs QYLD: Dividend Comparison 2026

ICVX yields 13.06% · QYLD yields 12.24%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ICVX wins by $20.7K in total portfolio value
10 years
ICVX
ICVX
● Live price
13.06%
Share price
$15.31
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.3K
Annual income
$2,943.04
Full ICVX calculator →
QYLD
Global X Nasdaq 100 Covered Call ETF
● Live price
12.24%
Share price
$16.70
Annual div
$2.04
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.5K
Annual income
$6,038.84
Full QYLD calculator →

Portfolio growth — ICVX vs QYLD

📍 ICVX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodICVXQYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ICVX + QYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ICVX pays
QYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ICVX
Annual income on $10K today (after 15% tax)
$1,110.39/yr
After 10yr DRIP, annual income (after tax)
$2,501.58/yr
QYLD
Annual income on $10K today (after 15% tax)
$1,040.82/yr
After 10yr DRIP, annual income (after tax)
$5,133.01/yr
At 15% tax rate, QYLD beats the other by $2,631.43/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ICVX + QYLD for your $10,000?

ICVX: 50%QYLD: 50%
100% QYLD50/50100% ICVX
Portfolio after 10yr
$36.9K
Annual income
$4,490.94/yr
Blended yield
12.17%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ICVX right now

ICVX
Analyst Ratings
5
Buy
1
Hold
Consensus: Buy
Price Target
$27.00
+76.4% upside vs current
Range: $27.00 — $27.00
Altman Z
22.6
Piotroski
3/9
QYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ICVX buys
0
QYLD buys
0
No recent congressional trades found for ICVX or QYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricICVXQYLD
Forward yield13.06%12.24%
Annual dividend / share$2.00$2.04
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$47.3K$26.5K
Annual income after 10y$2,943.04$6,038.84
Total dividends collected$21.0K$28.5K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: ICVX vs QYLD ($10,000, DRIP)

YearICVX PortfolioICVX Income/yrQYLD PortfolioQYLD Income/yrGap
1← crossover$12,006$1,306.34$10,384$1,224.49+$1.6KICVX
2$14,313$1,465.82$10,900$1,388.18+$3.4KICVX
3$16,948$1,633.07$11,576$1,590.76+$5.4KICVX
4$19,941$1,807.22$12,447$1,844.20+$7.5KICVX
5$23,324$1,987.33$13,567$2,164.97+$9.8KICVX
6$27,129$2,172.42$15,003$2,576.05+$12.1KICVX
7$31,390$2,361.53$16,853$3,110.04+$14.5KICVX
8$36,141$2,553.64$19,251$3,813.85+$16.9KICVX
9$41,419$2,747.79$22,390$4,756.08+$19.0KICVX
10$47,261$2,943.04$26,548$6,038.84+$20.7KICVX

ICVX vs QYLD: Complete Analysis 2026

ICVXStock

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; IVX-A12, a respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-241, a vaccine candidate with hMPV target; and IVX-411, an original receptor binding domain (RBD) sequence antigen with SARS-CoV-2 target indication and is under Phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in Seattle, Washington.

Full ICVX Calculator →

QYLDETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →
📬

Get this ICVX vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ICVX vs SCHDICVX vs JEPIICVX vs OICVX vs KOICVX vs MAINICVX vs XYLDICVX vs JEPQICVX vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.